Yu-Hung Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12024128/publications.pdf

Version: 2024-02-01

1477746 1588620 8 383 6 8 citations h-index g-index papers 8 8 8 843 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a metaâ€analysis and systemic review. Diabetes/Metabolism Research and Reviews, 2011, 27, 515-527.	1.7	276
2	Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitusâ€"a 4.6â€year cohort study. Diabetes/Metabolism Research and Reviews, 2016, 32, 557-564.	1.7	51
3	Reassessing the Benefits of Statins in the Prevention of Cardiovascular Disease in Diabetic Patients - A Systematic Review and Meta-Analysis. Review of Diabetic Studies, 2013, 10, 157-170.	0.5	14
4	Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Annals of Clinical Biochemistry, 2019, 56, 141-147.	0.8	12
5	<p>Common and Unique Factors and the Bidirectional Relationship Between Chronic Kidney Disease and Nonalcoholic Fatty Liver in Type 2 Diabetes Patients</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1203-1214.	1.1	12
6	Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus. Acta Diabetologica, 2017, 54, 561-568.	1.2	10
7	Paradoxical Negative HDL Cholesterol Response to Atorvastatin and Simvastatin Treatment in Chinese Type 2 Diabetic Patients. Review of Diabetic Studies, 2013, 10, 213-222.	0.5	6
8	Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3. Review of Diabetic Studies, 2016, 13, 212-214.	0.5	2